Clevidipine for severe hypertension in patients with renal dysfunction: A VELOCITY trial analysis

医学 血压 透析 肌酐 内科学 钙通道阻滞剂 二氢吡啶 肾功能 泌尿科 心脏病学 麻醉 钙
作者
W. Frank Peacock,Joseph Varón,Ramin Ebrahimi,Lala M. Dunbar,Charles V. Pollack
出处
期刊:Blood Pressure [Taylor & Francis]
卷期号:20 (sup1): 20-25 被引量:19
标识
DOI:10.3109/08037051.2010.539317
摘要

INTRODUCTION: Acute and severe hypertension is common, especially in patients with renal dysfunction (RD). Clevidipine is a rapidly acting (t½∼1 min) intravenous (IV) dihydropyridine calcium-channel blocker metabolized by blood and tissue esterases and may be useful in patients with RD. The purpose of this analysis was to assess the safety and efficacy of clevidipine in patients with RD. METHODS: VELOCITY, a multicenter open-label study of severe hypertension, enrolled 126 patients with persistent systolic blood pressure (SBP) >180 mmHg. Investigators pre-specified a SBP initial target range (ITR) for each patient to be achieved within 30 min. Blood pressure monitoring was by cuff. Clevidipine was infused via peripheral IV at 2 mg/h for at least 3 min, then doubled every 3 min as needed to a maximum of 32 mg/h (non-weight-based treat-to-target protocol). Per protocol, clevidipine was continued for at least 18 h (96 h maximum). RD was diagnosed and reported as an end-organ injury by the investigator and was defined as requiring dialysis or an initial creatinine >2.0 mg/dl. Primary endpoints were the percentage of patients within the ITR by 30 min and the percentage below the ITR after 3 min of clevidipine infusion. RESULTS: Of the 24 patients with moderate to severe RD, most (13/24) were dialysis dependent. Forty-six percent were male, with mean age 51 ± 14 years; 63% were black and 96% had a hypertension history. Median time to achieve the ITR was 8.5 min. Almost 90% of patients reached the ITR in 30 min without evidence of overshoot and were maintained on clevidipine through 18 h. Most patients (88%) transitioned to oral antihypertensive therapy within 6 h of clevidipine termination. CONCLUSIONS: This report is the first demonstrating that clevidipine is safe and effective in RD complicated by severe hypertension. Prolonged infusion maintained blood pressure within a target range and allowed successful transition to oral therapy.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
bobo完成签到 ,获得积分10
刚刚
zhi发布了新的文献求助10
刚刚
668898完成签到,获得积分10
刚刚
刚刚
1秒前
1秒前
1秒前
一期一会完成签到,获得积分10
1秒前
Tuilp发布了新的文献求助10
1秒前
3秒前
369ninja发布了新的文献求助10
4秒前
bobo关注了科研通微信公众号
4秒前
和谐乐发布了新的文献求助10
5秒前
dandelion完成签到 ,获得积分10
5秒前
6秒前
永毅发布了新的文献求助10
6秒前
6秒前
斯文败类的应助被Lachryz采纳,获得10
6秒前
Di发布了新的文献求助10
7秒前
JamesPei的应助被激动的绿竹采纳,获得10
7秒前
Akatin完成签到,获得积分10
8秒前
香蕉觅云的应助被saber采纳,获得10
8秒前
tnx完成签到,获得积分10
8秒前
科目三的应助被温暖的问候采纳,获得30
9秒前
Jasper的应助被hmy采纳,获得10
9秒前
脆薯片完成签到,获得积分10
9秒前
9秒前
10秒前
10秒前
shine完成签到 ,获得积分10
11秒前
发发发发完成签到,获得积分10
11秒前
东东发布了新的文献求助10
11秒前
xink完成签到,获得积分10
12秒前
阳光火车完成签到 ,获得积分0
12秒前
鹿鹿完成签到,获得积分10
12秒前
搜集达人的应助被cbw采纳,获得10
12秒前
水煮电吹风的应助被娜美采纳,获得10
12秒前
12秒前
13秒前
爆米花的应助被陶醉白梅采纳,获得10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181279
求助须知:如何正确求助?哪些是违规求助? 9571198
关于积分的说明 21817073
捐赠科研通 7777612
什么是DOI,文献DOI怎么找? 3433454
关于科研通互助平台的介绍 2557692
邀请新用户注册赠送积分活动 2479519